Orion Oyj

ORNBV

Equity

ISIN FI0009014377 / Valor 2553367

NASDAQ Helsinki Ltd, Equities (2024-11-21)

EUR 44.39-0.47%

Orion Oyj
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Orion Oyj is a globally operating Finnish pharmaceutical company engaged in the development, manufacturing, and marketing of pharmaceuticals, active pharmaceutical ingredients (APIs), and diagnostic tests. The company places a strong emphasis on collaboration and networking across its entire value chain, partnering with other entities in the pharmaceutical industry to enhance its research and development, manufacturing capabilities, and marketing reach. Through these partnerships, Orion aims to expand its product portfolio and strengthen its presence in the international market. While the company's specific product offerings are not detailed in the provided source, Orion's business model is indicative of a comprehensive approach to pharmaceutical and healthcare solutions, leveraging external expertise and resources to bolster its operations and product offerings.

Summarized from source with an LLMView SourceSector: Healthcare

Net Sales Growth

Orion Oyj reported net sales of EUR 636.7 million for the first half of 2024, marking a 12.2% increase compared to EUR 567.5 million in the same period of 2023. This growth was driven by strong performance in key product lines, including Nubeqa® and Easyhaler®.

Operating Profit Increase

For the first half of 2024, Orion Oyj's operating profit rose to EUR 121.8 million, a 19.5% increase from EUR 102.0 million in the first half of 2023. The increase in operating profit was attributed to higher sales and effective cost management.

Basic Earnings Per Share

Orion Oyj's basic earnings per share for the first half of 2024 were EUR 0.68, up from EUR 0.57 in the same period of 2023. This represents a 19.2% increase, reflecting the company's improved profitability.

Cash Flow from Operating Activities

Cash flow from operating activities per share for Orion Oyj in the first half of 2024 was EUR 0.98, significantly higher than the EUR 0.27 recorded in the first half of 2023. This substantial increase indicates stronger operational efficiency and cash generation.

Upgraded Financial Outlook

Following the strong performance in the first half of 2024, Orion Oyj upgraded its financial outlook for the year. The company now estimates net sales to be between EUR 1,440 million and EUR 1,480 million, and operating profit to range from EUR 350 million to EUR 380 million, up from the previous estimates of EUR 1,340 million to EUR 1,410 million in net sales and EUR 280 million to EUR 310 million in operating profit.

Summarized from source with an LLMView Source

Key figures

18.5%1Y

21.3%3Y

11.9%5Y

Performance

23.9%1Y

28.3%3Y

28.9%5Y

Volatility